RARE — Ultragenyx Pharmaceutical Inc. stock price, charts and financials

QT50Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
26.94
+1.03+3.98%
OverviewShort InterestFilings
RAREQT50Ultragenyx Pharmaceutical Inc.·NASDAQ
26.94+3.98%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AMLX-1.49%$22.48PGEN-2.63%$7.04TRVI-3.46%$17.87ZLAB+0.06%$23.34NRIX+1.18%$25.83PHVS+1.26%$35.35ATAI+0.14%$7.26KLRA+0.36%$18.73
Snapshot
Index-P/E-EPS (ttm)-6.11Insider Own4.11%Shs Outstand98.49MPerf Week4.01%
Market Cap2.55BForward P/E-EPS next Y-0.72Insider Trans-3.62%Shs Float94.61MPerf Month-25.14%
Enterprise Value2.43BPEG0.71EPS next Q-Inst Own-Short Float14.20%Perf Quarter-0.84%
Income-566.77MP/S3.56EPS this Y30.07%Inst Trans-Short Ratio6.24Perf Half Y8.91%
Sales716.92MP/B-EPS next Y83.22%ROA-46.39%Short Interest13.44MPerf YTD12.65%
Book/sh-P/C-EPS next 5Y-ROE392.35%52W High41.48 -35.05%Perf Year-7.63%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-57.93%52W Low19.02 41.66%Perf 3Y-38.82%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.85% 19.95%Gross Margin83.12%Volatility7.14% 5.48%Perf 5Y-67.54%
Dividend TTM-EV/Sales3.39EPS Y/Y TTM2.86%Oper. Margin-73.77%ATR (14)1.60Perf 10Y-57.53%
Dividend Ex-Date-Quick Ratio1.56Sales Y/Y TTM19.46%Profit Margin-81.79%RSI (14)42.01Recom2.24
Dividend Gr. 3/5Y-Current Ratio1.73EPS Q/Q-17.20%SMA20-6.04%Beta0.29Target Price46.00
Payout0.00%Debt/Eq0.00Sales Q/Q-2.16%SMA50-6.17%Rel Volume1.71Prev Close25.91
Employees1,371LT Debt/Eq-16.37EarningsNov 03SMA200-3.40%Avg Volume2.22MPrice26.94
IPO DateJan 31, 2014Option/ShortYes / YesEPS/Sales Surpr.-23.67% -14.03%Net Debt/EBITDA0.26Volume3,808,975Change3.98%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedGuggenheimBuy$43 → $35
Jul-13-26ReiteratedWedbushNeutral$26 → $30
Jul-07-26ReiteratedRBC CapitalOutperform$35 → $40
May-08-26ReiteratedWedbushNeutral$27 → $26
May-08-26ReiteratedGuggenheimBuy$52 → $43
Apr-29-26ReiteratedBarclaysOverweight$44 → $43
Apr-16-26ReiteratedMorgan StanleyOverweight$50 → $67
Mar-24-26DowngradeGoldman SachsBuy → Neutral
Mar-12-26ReiteratedLeerink Partners$85 → $60
Feb-18-26ReiteratedEvercore ISIOutperform$37 → $34
Latest News
Aug-06-26
Aug-06-2603:11AM
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up Following Strong Earningsdefenseworld.net
Aug-05-26
Aug-05-2612:51PM
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Yzacks.com
10:58AM
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $45Benzinga
05:40AM
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcriptseekingalpha.com
Aug-04-26
Aug-04-2610:05PM
Ultragenyx Pharmaceutical Q2 Earnings Call Highlightsmarketbeat.com
08:31PM
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com
08:02PM
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimateszacks.com
04:05PM
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Updateglobenewswire.com
Jul-28-26
Jul-28-2604:05PM
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Updateglobenewswire.com
11:06AM
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Declinezacks.com
Jul-27-26
Jul-27-2604:04AM
Entropy Technologies LP Grows Position in Ultragenyx Pharmaceutical Inc. $RAREdefenseworld.net
Jul-24-26
Jul-24-2604:30PM
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jul-23-26
Jul-23-2608:30AM
Brazilian Rare Earths June 2026 Quarterly Reportglobenewswire.com
Jul-22-26
Jul-22-2603:47AM
Fifth Third Bancorp Acquires New Holdings in Ultragenyx Pharmaceutical Inc. $RAREdefenseworld.net
Jul-21-26
Jul-21-2602:30AM
LEADING EDGE MATERIALS ADVANCES MIDSTREAM PROCESSING STRATEGY FOR THE NORRA KÄRR HEAVY RARE EARTH ELEMENTS PROJECTglobenewswire.com
Company

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue717673560——————
Cost of Goods Sold Incl. D&A12110977——————
Gross Profit596564484——————
Selling, General and Administrative Excl. Other352349322——————
Research and Development773750698——————
Other Operating Expense00-1——————
Operating Income-529-535-536——————
Interest Expense766263——————
Unusual Expense
—————————
Non-Operating Income (Expense)222631——————
Net Income Before Taxes-583-571-568——————
Income Taxes442——————
Consolidated Net Income-586-575-569——————
Net Income From Continuing Operations-586-575-569——————
Net Income-586-575-569——————
EPS (Recurring)-5.84-5.83-6.29——————
EPS (Basic, Before Extraordinaries)-5.84-5.83-6.29——————
EPS (Diluted)-5.84-5.83-6.29——————
EBITDA-473-474-469——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio3.833.386.84——————
Gross Margin83.1283.8086.43——————
Operating Margin-73.78-79.49-95.71——————
Net Margin-81.73-85.44-101.61——————
Shares Outstanding1029991——————
Market Capitalization2,7482,2773,828——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$44.88$37.43$29.97$22.51$15.06● Close Price0.00M0.63M1.26M1.90M2.53MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Horn HowardChief Financial OfficerAug 03 '26Sale24.924,696117,02496,295Aug 04
Parschauer Karah HerdmanEVP and Chief Legal OfficerAug 03 '26Sale24.921,90047,34892,562Aug 04
Horn HowardChief Financial OfficerJul 01 '26Sale33.134,698155,645100,991Jul 06
Parschauer Karah HerdmanEVP and Chief Legal OfficerJun 15 '26Sale24.621,89946,75394,462Jun 15
Sanders Corazon (Corsee) D.DirectorJun 15 '26Sale25.052,00050,10021,095Jun 15
Horn HowardChief Financial OfficerJun 01 '26Sale23.774,653110,602105,689Jun 01
SULIMAN SHEHNAAZDirectorMay 18 '26Sale25.125,740144,18927,951May 18
Crombez EricEVP and Chief Medical OfficerMay 05 '26Sale24.963448,586111,189May 06
Horn HowardChief Financial OfficerMay 01 '26Sale24.904,683116,607110,342May 04
Horn HowardChief Financial OfficerApr 01 '26Sale20.974,68398,20380,351Apr 02
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 10 '26Sale22.673,50879,52666,820Mar 10
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 06 '26Sale21.406,018128,78570,328Mar 10
Horn HowardChief Financial OfficerMar 03 '26Sale22.401,63536,62485,034Mar 03
Horn HowardChief Financial OfficerMar 02 '26Sale22.708,409190,91486,669Mar 03
Pinion John RichardSee RemarksMar 02 '26Sale22.8010,029228,661110,026Mar 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.